Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have been assigned a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $4.57.
Several analysts have recently issued reports on BDSI shares. HC Wainwright set a $5.00 price objective on BioDelivery Sciences International and gave the company a “buy” rating in a research report on Monday, November 27th. ValuEngine downgraded BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Seaport Global Securities started coverage on BioDelivery Sciences International in a research report on Friday, January 26th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, Zacks Investment Research upgraded BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Wednesday, February 14th.
Shares of BioDelivery Sciences International (NASDAQ:BDSI) opened at $2.15 on Wednesday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.28 and a quick ratio of 1.07. BioDelivery Sciences International has a 12-month low of $1.55 and a 12-month high of $3.60. The stock has a market capitalization of $120.15, a price-to-earnings ratio of -11.32 and a beta of 0.51.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BDSI. Royce & Associates LP purchased a new position in BioDelivery Sciences International during the third quarter worth about $3,814,000. Stonepine Capital Management LLC lifted its position in BioDelivery Sciences International by 11.2% during the third quarter. Stonepine Capital Management LLC now owns 3,867,400 shares of the specialty pharmaceutical company’s stock worth $11,409,000 after buying an additional 389,727 shares during the period. EAM Investors LLC lifted its position in BioDelivery Sciences International by 62.1% during the third quarter. EAM Investors LLC now owns 780,635 shares of the specialty pharmaceutical company’s stock worth $2,303,000 after buying an additional 299,163 shares during the period. Broadfin Capital LLC lifted its position in BioDelivery Sciences International by 5.1% during the fourth quarter. Broadfin Capital LLC now owns 4,634,119 shares of the specialty pharmaceutical company’s stock worth $13,671,000 after buying an additional 223,253 shares during the period. Finally, Millennium Management LLC purchased a new position in BioDelivery Sciences International during the fourth quarter worth about $310,000. Hedge funds and other institutional investors own 47.95% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/03/14/biodelivery-sciences-international-inc-bdsi-receives-average-recommendation-of-buy-from-brokerages.html.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.